glp 1 ckd benefit GLP-1 receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease The GLP-1 Era: Why These

2013;8(3):e58784

This service is not intended to replace consultation with a licensed medical professional.

16 As a secondary outcome, the trial demonstrated a 32% reduction in renal events with efpeglenatide (HR 0.68

No significant improvement in cellular physiologic status was observed in pancreas, liver, gall bladder and intestines in Cohort 2

[,] The bioinformatic analysis performed in this study clearly showed that L-carnitine might promote oxidation-associated cell apoptosis and production of hormones and improve glucose and lipid metabolism in the ovaries and whole body through the 6 identified core targets